http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018200562-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
filingDate 2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d5932b3ddb6d02d03fcc3f731db3453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72edbd9dde48e42e116c5c24421253f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4871718a99c440efeee17362a11495cb
publicationDate 2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2018200562-A1
titleOfInvention Compounds useful as inhibitors of ATR kinase and combination therapies thereof
abstract Abstract The present invention relates to compounds of Formula (1) that are useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. N (1)
priorityDate 2012-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407959408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466671321
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466679024
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467218174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425469352
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468176401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466345311
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412425200
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58070394

Total number of triples: 35.